Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free SKYE Stock Alerts

Skye Bioscience (SKYE) Financials

Skye Bioscience logo
$2.02 0.00 (0.00%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Skye Bioscience

Annual Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.84 -3.50 -4.14 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Consolidated Net Income / (Loss)		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Net Income / (Loss) Continuing Operations		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Total Pre-Tax Income 		-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Total Operating Income		 -4.32 -4.47 -3.86 -4.69 -6.63 -6.29 -7.85 -18 -35 -30 -58
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.32 4.47 3.86 4.69 6.63 6.29 7.85 18 35 34 58
Selling, General & Admin Expense		 3.74 3.53 3.55 4.36 4.39 4.34 4.92 6.09 7.85 18 16
Research & Development Expense		 0.58 0.94 0.31 0.33 2.24 1.94 2.93 6.01 5.82 19 42
Total Other Income / (Expense), net		 -0.52 1.29 0.77 -15 7.69 -0.27 -0.67 -1.16 -2.91 3.64 2.24
Interest Expense		 - 0.00 0.00 0.69 1.73 0.71 0.65 0.67 2.29 0.75 0.00
Interest & Investment Income		 - - 0.00 0.00 0.00 0.00 0.00 0.02 0.10 3.03 1.88
Other Income / (Expense), net		 -0.52 1.29 0.77 -14 9.41 0.44 -0.02 -0.52 -0.72 1.36 0.36
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01
Basic Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Basic Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 135.15M 230.75M 406.60M 2.22M 7.01M 36.49M 39.66M
Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Diluted Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 169.56M 231.42M 406.60M 2.22M 7.01M 36.49M 39.66M
Weighted Average Basic & Diluted Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M

Quarterly Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13 -11
Consolidated Net Income / (Loss)		 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Net Income / (Loss) Continuing Operations		 -4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13 -11
Total Pre-Tax Income 		-4.42 -5.02 -7.89 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Total Operating Income		 -4.09 -6.15 -8.41 -4.97 -11 -12 -18 -13 -15 -13 -11
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 4.09 6.15 8.41 4.97 15 12 18 13 15 13 11
Selling, General & Admin Expense		 2.49 4.21 4.33 4.64 4.55 4.56 3.91 3.91 3.43 4.74 3.87
Research & Development Expense		 1.59 1.95 4.08 4.88 7.79 7.20 14 9.36 11 7.94 3.94
Other Operating Expenses / (Income)		 - - - -4.55 - - - 0.00 - - 3.25
Total Other Income / (Expense), net		 -0.33 1.13 0.51 1.07 0.92 0.66 0.62 0.51 0.45 0.17 0.28
Interest Expense		 0.43 0.44 0.45 -0.09 -0.05 0.00 0.00 0.00 -0.00 0.00 0.00
Interest & Investment Income		 0.05 0.43 0.96 0.91 0.73 0.62 0.53 0.42 0.31 0.17 0.10
Other Income / (Expense), net		 0.05 1.14 -0.00 0.07 0.14 0.04 0.09 0.09 0.14 -0.00 0.18
Income Tax Expense		 - 0.00 0.01 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Weighted Average Basic Shares Outstanding		 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Diluted Earnings per Share		 ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Weighted Average Diluted Shares Outstanding		 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Weighted Average Basic & Diluted Shares Outstanding		 56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M 35.42M

Annual Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.01 -3.16 0.16 1.59 -0.02 0.64 6.51 -7.74 9.09 58 -63
Net Cash From Operating Activities		 -3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -25 -43
Net Cash From Continuing Operating Activities		 -3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -22 -43
Net Income / (Loss) Continuing Operations		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Consolidated Net Income / (Loss)		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Depreciation Expense		 0.01 0.01 0.01 0.00 0.00 0.00 0.03 0.11 0.12 0.30 0.72
Amortization Expense		 0.59 0.05 0.03 0.06 0.63 0.54 0.59 0.49 0.33 0.60 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.36 -0.58 0.05 15 -8.01 -0.13 0.76 6.83 24 6.45 7.23
Changes in Operating Assets and Liabilities, net		 -0.84 0.14 -0.32 0.10 0.30 0.09 0.66 -0.69 -0.39 -2.53 4.91
Net Cash From Investing Activities		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Net Cash From Continuing Investing Activities		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Purchase of Property, Plant & Equipment		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 -0.03 -0.01 -1.60 -0.01
Purchase of Investments		 - - - - - - - - - 0.00 -20
Divestitures		 - - - - - - 0.00 -0.07 5.53 1.36 0.36
Net Cash From Financing Activities		 6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Net Cash From Continuing Financing Activities		 6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Issuance of Common Equity		 0.72 0.00 0.00 3.19 6.00 6.13 13 0.00 4.97 0.00 0.03
Other Financing Activities, net		 - - 0.00 - - 0.00 0.02 0.00 12 84 0.00
Cash Interest Paid		 0.00 0.00 0.00 0.02 0.37 0.12 0.04 0.33 0.20 0.43 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01

Quarterly Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -3.87 82 -9.22 -6.71 -8.08 -22 -23 -5.40 -13 2.27 -0.08
Net Cash From Operating Activities		 -3.84 -4.71 -7.09 -5.26 -8.17 -9.19 -11 -13 -9.77 -8.56 -7.12
Net Cash From Continuing Operating Activities		 -3.84 -4.71 -7.34 -5.02 -4.69 -9.19 -11 -13 -9.77 -8.56 -7.12
Net Income / (Loss) Continuing Operations		 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Consolidated Net Income / (Loss)		 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13 -11
Depreciation Expense		 0.03 0.03 0.03 0.07 0.18 0.18 0.19 0.18 0.18 0.17 0.16
Non-Cash Adjustments To Reconcile Net Income		 0.41 1.33 1.81 -2.34 5.65 2.20 1.90 1.78 1.39 1.67 4.69
Changes in Operating Assets and Liabilities, net		 -0.09 -1.29 -1.52 1.05 -0.78 -0.46 4.79 -2.57 3.11 2.10 -1.19
Net Cash From Investing Activities		 -0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11 7.14
Net Cash From Continuing Investing Activities		 -0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11 7.14
Sale and/or Maturity of Investments		 - - - - - -13 - - - 11 6.96
Net Cash From Financing Activities		 -0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07 -0.10
Net Cash From Continuing Financing Activities		 -0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07 -0.10
Repayment of Debt		 -0.03 - - - - 0.00 - - - -0.07 -0.11
Cash Interest Paid		 - - - - - 0.00 - - - 0.00 0.00
Cash Income Taxes Paid		 - - - - - 0.00 - - - 0.00 0.00

Annual Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Current Assets		 3.45 0.28 0.56 1.95 1.99 2.66 9.61 8.94 12 71 27
Cash & Equivalents		 3.22 0.06 0.26 1.85 1.83 2.47 8.98 1.24 1.26 68 5.88
Short-Term Investments		 - - - - - - - - - 0.00 20
Prepaid Expenses		 0.16 0.17 0.29 0.09 0.15 0.19 0.55 0.78 0.19 0.20 0.50
Other Current Assets		 0.04 0.01 0.00 0.00 0.01 0.00 0.06 0.48 1.12 2.21 0.85
Plant, Property, & Equipment, net		 0.01 0.01 0.00 0.00 0.00 0.01 0.09 0.09 0.04 1.43 0.90
Total Noncurrent Assets		 0.04 0.03 0.00 0.00 0.00 0.00 0.16 0.08 0.25 0.50 0.32
Other Noncurrent Operating Assets		 0.04 0.03 - - - 0.00 0.16 0.08 0.25 0.50 0.32
Total Liabilities & Shareholders' Equity		 3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Liabilities		 3.04 1.77 1.36 18 1.45 2.22 3.99 12 14 4.61 8.29
Total Current Liabilities		 0.58 0.66 0.81 16 0.97 0.79 3.91 12 14 4.34 8.21
Short-Term Debt		 - 0.00 0.24 - 0.00 0.00 1.97 1.85 4.37 - 0.00
Accounts Payable		 0.13 0.27 0.10 0.02 0.14 0.38 0.90 1.79 0.96 0.57 2.03
Accrued Expenses		 0.37 0.27 0.20 - 0.00 - 0.00 6.21 6.26 1.82 2.07
Current Employee Benefit Liabilities		 - - - - - 0.06 0.34 0.66 0.89 1.11 1.27
Other Current Liabilities		 0.08 0.12 0.27 16 0.83 0.34 0.69 1.60 1.06 0.84 2.83
Total Noncurrent Liabilities		 2.46 1.11 0.55 1.58 0.48 1.43 0.08 0.00 0.17 0.27 0.08
Other Noncurrent Operating Liabilities		 2.45 1.11 0.55 0.22 0.09 0.00 0.08 0.00 0.17 0.27 0.08
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Total Preferred & Common Equity		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Common Stock		 6.11 7.18 9.48 18 33 39 53 64 102 199 207
Retained Earnings		 -7.76 -11 -14 -33 -32 -39 -47 -67 -104 -131 -187

Quarterly Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 16 95 87 82 65 52 41 19 11
Total Current Assets		 15 95 87 80 63 51 40 19 11
Cash & Equivalents		 5.13 83 74 67 46 24 18 8.15 8.07
Short-Term Investments		 - - - - 13 25 17 8.96 2.00
Prepaid Expenses		 0.21 0.64 1.10 0.66 0.58 1.26 3.71 1.22 0.42
Other Current Assets		 0.87 1.51 2.71 2.65 3.23 0.73 0.90 0.23 0.48
Plant, Property, & Equipment, net		 0.06 0.04 0.05 1.52 1.30 1.17 1.03 0.76 0.03
Total Noncurrent Assets		 0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09 0.04
Other Noncurrent Operating Assets		 0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09 0.04
Total Liabilities & Shareholders' Equity		 16 95 87 82 65 52 41 19 11
Total Liabilities		 14 16 14 5.73 5.54 8.48 8.49 10 12
Total Current Liabilities		 14 16 14 5.62 5.32 8.31 8.37 10 12
Short-Term Debt		 4.17 4.61 4.86 0.00 - - - 0.25 0.14
Accounts Payable		 1.64 1.10 1.08 0.78 1.71 3.22 2.83 3.94 4.28
Accrued Expenses		 6.21 6.05 6.05 1.79 1.91 1.81 2.05 2.57 5.42
Current Employee Benefit Liabilities		 0.65 0.35 0.56 0.90 0.66 0.87 0.92 0.23 0.69
Other Current Liabilities		 1.05 3.38 1.39 2.15 1.04 2.42 2.57 3.41 1.00
Total Noncurrent Liabilities		 0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00 0.00
Other Noncurrent Operating Liabilities		 0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.70 79 73 76 59 44 33 9.01 -0.50
Total Preferred & Common Equity		 1.70 79 73 76 59 44 33 9.01 -0.50
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.70 79 73 76 59 44 33 9.01 -0.50
Common Stock		 102 188 190 197 201 203 205 208 210
Retained Earnings		 -100 -109 -117 -121 -142 -160 -172 -199 -210

Annual Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Adjusted Shares Outstanding		 19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.25 -0.17 -0.13 -0.14 0.01 -0.03 -0.02 -0.02 -3.05 -1.02 -1.74
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -55.49% 26.73% 1.80% -504.04% 118.49% -255.61% -36.45% -151.68% -92.04% 20.17% -104.30%
EBIT Growth		 -77.16% 34.36% 2.66% -498.56% 115.02% -310.57% -34.45% -139.28% -88.28% 18.66% -100.45%
NOPAT Growth		 -58.04% -3.55% 13.68% -21.59% -101.61% 33.53% -24.78% -133.34% -89.69% 13.08% -92.64%
Net Income Growth		 -77.06% 34.35% 2.64% -520.31% 105.48% -723.74% -29.90% -128.60% -93.23% 29.43% -110.50%
EPS Growth		 -7.41% 41.38% 35.29% -45.45% 68.75% 40.00% 33.33% -43,750.00% 38.77% 86.41% -93.15%
Operating Cash Flow Growth		 -112.40% 4.70% 6.24% -18.36% -52.88% -0.43% -6.95% -96.82% -9.48% -80.89% -70.63%
Free Cash Flow Firm Growth		 23.68% -387.51% 21.51% 448.74% -282.36% 78.37% -4.71% -4.20% -394.10% -12.61% -23.28%
Invested Capital Growth		 -321.82% 44.28% 46.60% -1,836.10% 94.40% 34.46% -94.84% -668.41% 12.35% 96.59% -2,063.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 12.71% -18.46% 14.06% -44.27% 138.21% -375.74% -15.28% -72.76% 14.69% -30.72% -8.00%
EBIT Q/Q Growth		 0.50% -15.63% 13.72% -44.21% 129.60% -539.99% -14.51% -66.74% 14.08% -29.02% -7.90%
NOPAT Q/Q Growth		 11.24% 5.14% -1.97% -7.54% -54.98% 7.70% -17.04% -59.37% 13.01% -27.87% -7.84%
Net Income Q/Q Growth		 17.28% -15.62% 13.73% -41.13% 110.49% -3,076.48% -13.46% -60.97% 12.69% -25.08% -9.17%
EPS Q/Q Growth		 32.56% -30.77% 45.00% -45.45% 50.00% -200.00% 0.00% -448.13% 57.07% -43.14% -9.30%
Operating Cash Flow Q/Q Growth		 14.82% 11.26% -80.02% 22.26% -8.83% -4.90% -2.91% -29.49% 6.86% -20.70% -3.84%
Free Cash Flow Firm Q/Q Growth		 -199.12% 17.30% -82.75% 98.69% -1,952.86% 73.42% 4.25% 34.37% -22.00% -18.27% 1.95%
Invested Capital Q/Q Growth		 16.89% -12.83% 61.45% -43.15% 93.77% 59.88% -13.80% -623.99% 7.34% 61.71% -130.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.04% 100.05% 100.05% 100.01% 99.85% 100.02% 100.02% 100.03% 100.01% 100.04% 100.01%
Interest Burden Percent		 100.00% 100.00% 100.02% 103.70% 37.90% 112.07% 108.28% 103.43% 106.18% 92.10% 96.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55,492.45% 648.65% 274.93% 234.62% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,280,093.44% 2,519.68% 791.91% 274.33% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Return on Equity Simple (ROE_SIMPLE)		 542.61% 109.05% 86.69% 123.34% 191.92% -1,455.39% -145.33% 647.65% 1,765.85% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -13 -24 -21 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -104.97% -2.90% -596.55% -6,045.68% 789.39% -173.53% -75.22% -103.87% -233.43% -14.68% -32.31%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -1,085.39% -31.01% -203.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.84 -3.18 -3.09 -19 2.78 -5.85 -7.87 -19 -35 -29 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.24 -3.11 -3.05 -18 3.41 -5.31 -7.24 -18 -35 -28 -57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 16.64 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 6.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 4.71 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 5.78 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -0.29 -0.09 0.71 3.18 0.34 -0.61 -2.05 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.09 0.71 3.18 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -198.65 3.43 0.06 0.03 0.13 -2.49 -1.28 -4.49 2.22 -1.12 -1.07
Leverage Ratio		 221.19 -3.91 -0.39 -0.15 -0.26 4.67 1.98 6.64 -4.10 1.28 1.15
Compound Leverage Factor		 221.19 -3.91 -0.39 -0.16 -0.10 5.24 2.15 6.87 -4.35 1.18 1.11
Debt to Total Capital		 0.00% 0.00% -41.59% -9.58% 41.39% 76.08% 25.19% -159.39% 195.16% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% -41.59% 0.00% 0.00% 0.00% 25.19% -159.39% 195.16% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -9.58% 41.39% 76.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 289.43% -100.86% -490.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -189.43% 200.86% 631.68% 109.58% 58.61% 23.92% 74.81% 259.39% -95.16% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.08 -0.07 0.11 -0.27 -0.27 -0.10 -0.12 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.01 0.03 -0.42 0.20 0.97 -0.03 0.17 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.07 0.11 -0.27 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.09 -0.41 -0.06 -0.33 -0.36 -0.14 -0.18 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.01 0.15 0.22 0.24 1.28 -0.05 0.25 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.41 -0.06 -0.33 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.00 -79.06 -52.02 -61.71 -10.10 -23.98 -4.93 -16.76 -20.83 8.44 -13.44
Noncontrolling Interest Sharing Ratio		 7,812.93% -288.45% -188.04% -16.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.94 0.42 0.69 0.12 2.05 3.38 2.46 0.74 0.84 16.32 3.30
Quick Ratio		 5.54 0.10 0.32 0.12 1.89 3.14 2.30 0.10 0.09 15.77 3.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.90 -4.36 -3.43 12 -22 -4.71 -4.93 -5.14 -25 -29 -35
Operating Cash Flow to CapEx		 -188,092.28% -31,959.53% -16,949.65% -89,920.50% 0.00% -83,736.25% -7,125.75% -45,417.22% -111,172.73% -1,573.38% -682,232.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -5,135.27 17.43 -12.62 -6.67 -7.58 -7.73 -11.10 -38.18 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -4,994.43 -5.75 -3.49 -8.57 -9.94 -19.16 -6.09 -33.68 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -5,023.90 -5.76 -3.49 -8.58 -10.08 -19.20 -6.10 -35.82 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.79 -1.55 -0.83 -16 -0.90 -0.59 -1.15 -8.83 -7.74 -0.26 -5.71
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.13 1.23 0.72 -15 15 0.31 -0.56 -7.68 1.09 7.47 -5.45
Enterprise Value (EV)		 12 7.64 7.45 53 16 8.96 18 15 28 17 -1.70
Market Capitalization		 13 6.28 4.71 54 17 10 25 15 34 86 24
Book Value per Share		 ($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Tangible Book Value per Share		 ($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Total Capital		 0.47 -1.45 -0.57 -14 0.94 1.88 7.84 -1.16 2.24 68 20
Total Debt		 0.00 0.00 0.24 1.36 0.39 1.43 1.97 1.85 4.37 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 1.36 0.39 1.43 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 0.60 -5.96 -68 -26
Capital Expenditures (CapEx)		 0.00 0.01 0.02 0.00 0.00 0.01 0.09 0.03 0.01 1.60 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.39 -0.48 -0.28 -16 -0.81 -0.60 -1.31 -2.58 -8.21 -1.93 -6.85
Debt-free Net Working Capital (DFNWC)		 2.87 -0.38 -0.02 -14 1.02 1.88 7.67 -1.33 2.12 66 19
Net Working Capital (NWC)		 2.87 -0.38 -0.25 -14 1.02 1.88 5.70 -3.18 -2.25 66 19
Net Nonoperating Expense (NNE)		 1.82 0.05 0.39 16 -7.67 2.16 3.03 6.66 13 5.43 15
Net Nonoperating Obligations (NNO)		 -3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 -5.82 -5.60 -68 -26
Total Depreciation and Amortization (D&A)		 0.60 0.07 0.04 0.06 0.63 0.55 0.63 0.60 0.45 0.90 0.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Basic Shares Outstanding		 19.90M 25.73M 27.91M 133.91M 135.15M 230.75M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Diluted Shares Outstanding		 19.90M 25.73M 27.91M 133.91M 169.56M 231.42M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Basic & Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 16.94M 18.95M 100.08M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -8.47 -24 -23 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -4,635.73 -27.01 1.61 -8.29 -12.08 -28.31 -15.48 -38.48 0.00
NOPAT to Interest Expense		 0.00 0.00 -4,050.17 -4.79 -3.84 -6.23 -8.44 -19.27 -10.62 -28.21 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -4,665.19 -27.02 1.61 -8.30 -12.22 -28.35 -15.49 -40.62 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -4,079.63 -4.80 -3.84 -6.24 -8.58 -19.31 -10.63 -30.35 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00 35,143,722.00
DEI Adjusted Shares Outstanding		 12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00 35,143,722.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.36 -0.18 -0.28 -0.13 -0.46 -0.36 -0.57 -0.41 -0.45 -0.37 -0.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 61.42% -26.25% -180.57% 80.78% -173.51% -143.32% -121.12% -175.34% -40.83% -8.34% 40.31%
EBIT Growth		 58.98% -32.13% -186.89% 80.17% -160.53% -134.00% -115.97% -169.02% -40.20% -8.17% 40.05%
NOPAT Growth		 55.98% -98.45% -195.66% 79.89% -161.02% -91.14% -117.05% -166.96% -39.65% -7.78% 39.37%
Net Income Growth		 55.32% 2.86% -153.99% 84.37% -120.51% -121.20% -123.02% -227.19% -48.18% -12.66% 38.80%
EPS Growth		 99.58% 86.86% 75.00% 96.85% -733.33% -55.56% -120.00% -220.00% -48.00% -14.29% 38.64%
Operating Cash Flow Growth		 21.08% -15.94% -256.13% -29.79% -112.58% -95.10% -51.49% -153.94% -19.50% 6.83% 33.73%
Free Cash Flow Firm Growth		 -435.15% -167.28% -265.23% -9.57% -278.19% -466.18% -44.67% 32.67% 66.68% 94.08% 82.84%
Invested Capital Growth		 12.35% -18.17% 37.66% 91.74% 96.59% 100.31% 4.64% -259.15% -2,063.89% -29,861.00% -112.25%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 84.59% -25.35% -71.31% 41.92% -119.32% -11.51% -55.68% 27.68% -12.18% 14.22% 14.22%
EBIT Q/Q Growth		 83.64% -23.96% -67.85% 41.75% -114.95% -11.34% -54.92% 27.44% -12.02% 14.09% 14.15%
NOPAT Q/Q Growth		 83.46% -50.56% -36.63% 40.89% -114.66% -10.25% -55.14% 27.29% -12.30% 14.91% 12.73%
Net Income Q/Q Growth		 82.28% -13.57% -57.44% 50.67% -150.02% -13.92% -58.74% 27.63% -13.23% 13.38% 13.77%
EPS Q/Q Growth		 99.05% -500.00% -11.11% 50.00% -150.00% -12.00% -57.14% 27.27% -15.63% 13.51% 15.63%
Operating Cash Flow Q/Q Growth		 5.18% -22.46% -50.67% 25.81% -55.30% -12.39% -16.99% -24.36% 26.92% 12.37% 16.78%
Free Cash Flow Firm Q/Q Growth		 61.14% 24.53% -201.66% -23.85% -34.12% -12.99% 22.92% 42.36% 33.62% 79.93% -123.49%
Invested Capital Q/Q Growth		 7.34% -11.44% 40.29% 86.61% 61.71% 109.99% -18,717.77% 49.56% -130.73% -37.34% -32.78%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.04% 100.10% 100.00% 100.00% 100.02% 100.02% 100.00% 100.00% 100.00% 100.03%
Interest Burden Percent		 109.40% 100.19% 93.92% 79.61% 92.60% 94.73% 97.06% 96.82% 97.87% 98.68% 99.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97% -233.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -127,847.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97% -233.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -47.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87 -7.74
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -27.31% -1.58% -5.15% -0.97% -6.16% -3.91% -7.67% -6.21% -8.53% -9.56% -10.40%
Return On Investment Capital (ROIC_SIMPLE)		 -127.69% -5.16% -7.58% -4.59% -10.96% -13.89% -29.24% -28.28% -52.07% -95.79% 2,185.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.04 -5.01 -8.41 -4.90 -11 -12 -18 -13 -15 -13 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.78 -4.74 -8.13 -4.72 -10 -12 -18 -13 -15 -13 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28 0.00
Price to Tangible Book Value (P/TBV)		 0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.03 -0.29
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 2.22 -1.21 -1.21 -1.12 -1.12 -1.06 -1.09 -1.03 -1.07 -1.11 -1.36
Leverage Ratio		 -4.10 1.34 1.38 1.25 1.28 1.16 1.20 1.13 1.15 1.23 1.46
Compound Leverage Factor		 -4.48 1.34 1.29 1.00 1.19 1.09 1.16 1.10 1.12 1.22 1.45
Debt to Total Capital		 195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70% -40.38%
Short-Term Debt to Total Capital		 195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70% -40.38%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -95.16% 94.48% 93.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.30% 140.38%
Debt to EBITDA		 -0.12 -0.13 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.17 2.44 1.90 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.20
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.18 -0.17 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 0.00
Net Debt to NOPAT		 0.25 3.32 2.58 0.00 0.00 0.00 0.00 0.00 0.00 0.41 0.27
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -12.15 15.72 8.13 11.23 9.27 2.73 4.70 2.63 -8.42 -14.84 -28.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.84 5.99 6.07 14.19 16.32 11.85 6.09 4.77 3.30 1.78 0.95
Quick Ratio		 0.09 5.27 5.18 11.99 15.77 11.13 5.85 4.22 3.14 1.64 0.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.95 -2.98 -8.99 -11 -15 -17 -13 -7.50 -4.98 -1.00 -2.23
Operating Cash Flow to CapEx		 -54,791.48% -148,007.64% -21,851.14% -346.61% -16,338.36% -145,524.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -9.18 -6.82 -19.98 0.00 0.00 -11,624.48 0.00 0.00 0.00 -454.39 -676.90
Operating Cash Flow to Interest Expense		 -8.94 -10.78 -15.76 0.00 0.00 -6,326.09 0.00 0.00 0.00 -3,891.73 -2,158.74
Operating Cash Flow Less CapEx to Interest Expense		 -8.95 -10.78 -15.83 0.00 0.00 -6,330.44 0.00 0.00 0.00 -3,891.34 -2,158.74
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.74 -8.62 -5.15 -0.69 -0.26 0.03 -4.91 -2.48 -5.71 -7.85 -10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.09 -1.33 3.11 7.66 7.47 8.65 0.24 -1.79 -5.45 -7.87 -5.51
Enterprise Value (EV)		 28 351 146 42 17 -9.97 81 86 -1.70 3.66 14
Market Capitalization		 34 439 225 119 86 49 130 122 24 21 24
Book Value per Share		 ($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27 ($0.01)
Tangible Book Value per Share		 ($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27 ($0.01)
Total Capital		 2.24 83 78 76 68 59 44 33 20 9.26 -0.35
Total Debt		 4.37 4.61 4.86 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.14
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.96 -88 -78 -76 -68 -59 -49 -35 -26 -17 -9.92
Capital Expenditures (CapEx)		 0.01 0.00 0.03 1.52 0.05 0.01 0.00 0.00 0.00 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.21 -9.04 -5.66 -2.31 -1.93 -1.52 -6.31 -3.76 -6.85 -8.70 -10
Debt-free Net Working Capital (DFNWC)		 2.12 83 78 74 66 58 42 32 19 8.41 -0.43
Net Working Capital (NWC)		 -2.25 79 73 74 66 58 42 32 19 8.16 -0.57
Net Nonoperating Expense (NNE)		 1.56 0.71 2.02 0.42 2.28 2.87 4.85 3.47 4.02 3.64 3.04
Net Nonoperating Obligations (NNO)		 -5.60 -88 -78 -76 -68 -59 -49 -35 -26 -17 -9.92
Total Depreciation and Amortization (D&A)		 0.26 0.26 0.28 0.18 0.18 0.18 0.19 0.18 0.18 0.17 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding		 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Adjusted Diluted Earnings per Share		 ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M 39.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M 35.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87 -7.74
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -9.39 -11.46 -18.68 0.00 0.00 -8,070.88 0.00 0.00 0.00 -5,764.79 -3,298.91
NOPAT to Interest Expense		 -6.65 -9.86 -13.07 0.00 0.00 -5,669.21 0.00 0.00 0.00 -4,034.59 -2,347.05
EBIT Less CapEx to Interest Expense		 -9.41 -11.47 -18.75 0.00 0.00 -8,075.23 0.00 0.00 0.00 -5,764.41 -3,298.91
NOPAT Less CapEx to Interest Expense		 -6.67 -9.86 -13.15 0.00 0.00 -5,673.56 0.00 0.00 0.00 -4,034.20 -2,347.05
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Skye Bioscience’s latest quarter shows a strong cash position, but also continued heavy losses and cash burn. For Q1 2026, the company reported no revenue, a net loss of $12.5 million, and negative operating cash flow of $8.6 million. That said, Skye still had $8.1 million in cash and $9.0 million in short-term investments at quarter-end, giving it a meaningful liquidity cushion.

Balance sheet and liquidity trends have weakened significantly from a year ago. Total assets were $19.4 million in Q1 2026, down sharply from $64.8 million in Q1 2025 and $94.8 million in Q1 2024. Cash and investments also declined from $59.2 million in Q1 2025 and $96.1 million in Q1 2024 to about $17.1 million combined in Q1 2026, reflecting sustained spending on research and development.

Operating performance remains pre-commercial. Skye generated zero revenue across all periods shown, so the business is still entirely dependent on financing and investment income to fund operations. Q1 2026 operating expenses totaled $12.7 million, including $7.9 million in R&D and $4.7 million in SG&A.

Cash burn is the key issue. Operating cash flow was negative in every period provided, including -$8.6 million in Q1 2026, -$9.8 million in Q4 2025, and -$10.7 million in Q2 2025. While Skye’s investing activity boosted cash in Q1 2026 through $10.9 million of investment sales/maturities, that is not a recurring source of cash.

Year-over-year, losses are somewhat smaller in the latest quarter versus Q1 2025, when the company posted a $11.1 million net loss and $9.2 million operating cash outflow. However, the bigger-picture trend still shows a company spending heavily with no revenue offset.

  • $17.1 million combined in cash and short-term investments at the end of Q1 2026 provides some near-term liquidity.
  • Operating cash burn improved versus Q4 2025 and Q2 2025, with Q1 2026 operating cash outflow narrowing to $8.6 million.
  • Interest and investment income of $169,615 helped partially offset losses in Q1 2026.
  • Debt levels are low relative to liquidity, with only $250,338 of short-term debt reported in Q1 2026.
  • No revenue was reported, which is normal for a development-stage biotech but leaves the stock highly dependent on clinical progress and financing access.
  • R&D spending remains substantial at $7.9 million in Q1 2026, indicating the company is still investing in pipeline development.
  • Share count stayed relatively stable near 39.7 million weighted average basic shares in Q1 2026 versus 39.7 million in Q4 2025.
  • Net loss of $12.5 million in Q1 2026 shows the company is still far from profitability.
  • Total assets fell sharply from $64.8 million in Q1 2025 to $19.4 million in Q1 2026.
  • Cash and equivalents dropped from $46.4 million in Q1 2025 to $8.1 million in Q1 2026, underscoring continued cash consumption.

Bottom line: Skye Bioscience remains a speculative biotech story. The company still has enough cash and marketable securities to operate in the near term, but the combination of no revenue, persistent losses, and ongoing cash burn means investors should expect continued reliance on capital markets unless clinical results materially change the outlook.

08/26/26 09:30 PM ETAI Generated. May Contain Errors.

Skye Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Skye Bioscience's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Skye Bioscience's net income appears to be on an upward trend, with a most recent value of -$55.92 million in 2025, rising from -$4.84 million in 2015. The previous period was -$26.57 million in 2024. See where experts think Skye Bioscience is headed by visiting Skye Bioscience's forecast page.

Skye Bioscience's total operating income in 2025 was -$58.16 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.16 million

Over the last 10 years, Skye Bioscience's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Skye Bioscience's total liabilities were at $8.29 million at the end of 2025, a 79.7% increase from 2024, and a 172.7% increase since 2015.

In the past 10 years, Skye Bioscience's cash and equivalents has ranged from $64.82 thousand in 2016 to $68.42 million in 2024, and is currently $5.88 million as of their latest financial filing in 2025.

Over the last 10 years, Skye Bioscience's book value per share changed from -0.05 in 2015 to 0.62 in 2025, a change of -1,449.0%.


Related Companies

Financial statements for NASDAQ:SKYE last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel